ALLARITY THERAPEUTICS INC ALLR
ASignal's systematic analysis rates ALLR as Bearish.
Reflects the latest available analysis · analyzed Nov 12, 2026
The case on ALLR
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Price above 20-day SMA and near Bollinger lower band suggesting potential reversal
- Positive MACD histogram indicating strengthening momentum
- High gross margin of 100% typical of early-stage biotech with proprietary technology
- Cash runway supported by $16.98M cash against $22.29M debt
- Extremely high debt-to-equity ratio of 6.30x
- Negative operating margin at -3128.99%
- Negative return on equity at -157.09%
- Negative free cash flow of $-19.77M
- EV/Revenue of 58.51x and PS ratio of 43.13x indicating high valuation risk
- No news coverage or Reddit mentions indicating low market sentiment
See the full verdict on ALLR
ASignal Rank (1-4), confidence score, Value / Activist / Macro grades, price targets, and the full reasoning behind the call.
How ASignal analyzes ALLR
Most investors never get a second opinion, let alone several. ASignal runs ALLR past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: value discipline, activist catalysts, and macro analysis. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.